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Lack of Association between BRAF Mutation and
MAPK ERK Activation in Melanocytic Nevi
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The mitogen-activated protein kinase (MAPK) extracellular signal-regulated kinase signaling pathway can be
activated through mutations of V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) oncogene, frequently
found in melanoma (60%), common nevi (CN) (73–82%), and atypical nevi (AN) (52–80%). MAPK activation has
been reported between 0 and 22% in nevi, and 86% of primary melanoma, without any knowledge of BRAF
mutational status. We studied the correlation of MAPK activation status, BRAF mutation, and B-Raf expression in
CN, AN, and melanoma. Using immunohistochemistry, phosphorylated (active) MAPK and B-Raf expression was
studied in 24 CN, 21 AN, and 26 primary cutaneous melanomas (PM). BRAF mutations at codon 600 were
assessed by PCR-RFLP. Active MAPK was detected in 29% of CN, 48% of AN, and 85% of PM. BRAF mutation was
found in 67% of CN, 62% of AN, and 58% of PM. In all, 23% of CN, 54% of AN, and 93% of PM with BRAF
mutation have activated MAPK. All lesions expressed B-Raf. BRAF mutation does not seem to be sufficient to
produce MAPK activation in melanocytic nevi, and it is suggested that other events are needed to induce MAPK
activation, that is, B-Raf overexpression, inhibition of MAPK phosphatases, or suppression of RAF kinase
inhibitors.
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INTRODUCTION
Cutaneous melanoma is the most lethal skin cancer, and its
overall incidence has risen rapidly in the last decades (Jemal
et al., 2003). In human melanocytic proliferations, there are a
number of discrete lesions, including benign nevi, dysplastic
or atypical nevi (AN), and in situ and invasive melanomas
(Clark et al., 1984). Although commonly AN are considered
as stable melanocytic proliferations, it is also thought that
they represent both a marker of increased risk for melanoma
and a potential precursor lesion (Rhodes et al., 1983; Duray
and Ernstoff, 1987), because many melanomas (up to 30%)
seem to arise from pre-existing AN (Sober and Burstein,
1995).
Although the pathogenetic mechanisms underlying mela-
nocytic transformation are still largely unknown, melanoma
seems to be related to both environmental and genetic factors
(Polsky et al., 2001). Some of the key processes underlying
human tumor development and progression are tumor
suppressor gene inactivation, impaired DNA repair, and
dominant oncogene activation (Hahn and Weinberg, 2002).
In melanoma, a number of genetic abnormalities affecting a
variety of these genes have been reported, including
CDKN2A and PTEN inactivation (Pollock and Trent, 2000)
and RAS and V-RAF murine sarcoma viral oncogene homolog
B1 (BRAF) oncogene mutation (Davies et al., 2002; Omholt
et al., 2002).
The RAS–RAF–mitogen activated protein kinase kinase/
extracellular signal-regulated kinase kinase (MEK)–extracel-
lular signal-regulated kinase (ERK) or mitogen-activated
protein kinase (MAPK) ERK is an important pathway that
mediates cellular responses to growth signals (Peyssonnaux
and Eychene, 2001), and can be activated in melanoma
through growth factors, and RAS and BRAF mutations. RAS
mutation frequency (especially N-RAS) varies between 5 and
36% (Omholt et al., 2002). BRAF activating mutations have
been found in a high proportion of melanomas (56–66%), AN
(52–80%), and common nevi (CN) (73–82%) (Davies et al.,
2002; Pollock et al., 2003; Uribe et al., 2003). BRAF encodes
a serine/threonine kinase that transduces regulatory signals
from Ras to Mek1/2. BRAF mutations are within the kinase
domain, with a single substitution in exon 15 (T1799A) at
codon 600 (V600E) accounting for 83% of BRAF mutations in
primary melanoma and 95% in melanoma cell lines (Davies
et al., 2002). Mutated B-Raf proteins have elevated kinase
activity, induce ERK activation, and transform NIH3T3 cells
(Davies et al., 2002). The importance of this MAPK pathway
in melanocytic malignant transformation and melanoma
progression is partially reflected in the fact that introduction
of MEK activated or V600EBRAF into immortalized murine
melanocytes leads to tumorigenesis in vitro and in vivo
(Govindarajan et al., 2003; Wellbrock et al., 2004).
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While BRAF mutation is frequently found in melanomas
and nevi, and is considered an early event in the pathogen-
esis of melanocytic lesions (Davies et al., 2002; Pollock et al.,
2003; Uribe et al., 2003; Kumar et al., 2004; Miller et al.,
2004), MAPK ERK1/2 activation is reported only between 0
and 22% in nevi, and 54–86% of primary melanomas (Cohen
et al., 2002; Jorgensen et al., 2003; Satyamoorthy et al.,
2003), suggesting that in nevi BRAF mutation is not sufficient
to induce MAPK activation in vivo. Previous studies have not
simultaneously analyzed BRAF mutation and MAPK activa-
tion in CN and AN. On the other hand, there is no
information regarding B-Raf expression in human melanocy-
tic lesions in vivo.
In the present study, we show that ERK1/2 is more
frequently activated in AN than in CN, but there is a lack of
association between BRAF mutation and ERK1/2 activation in
melanocytic nevi. B-Raf is expressed in all melanocytic
lesions analyzed.
RESULTS
Expression of activated ERK1/2 in CN, AN, and cutaneous
melanoma
The antibody used in the present study detects ERK1/2 only
when it is catalytically activated (phospho-ERK1/2) by
phosphorylation at Thr202 and Tyr204 (Albanell et al.,
2001; Arbiser et al., 2001). The specificity of phospho-
ERK1/2 antibody was confirmed by immunostaining forma-
lin-fixed, paraffin-embedded cytoblock preparations of the
melanoma cell line SK-MEL-28 grown in cell medium with
serum (Figure 1a) and the same cells in starvation, and treated
with an inhibitor of MEK, U0126 (Figure 1b). Endothelial cells
and lymphocytes were considered as internal positive and
negative controls for each slide (Figure 1c), as used by others
(Gioeli et al., 1999; Albanell et al., 2001). A heterogeneous
cytoplasmic and/or nuclear staining pattern was observed as
a positive immunostaining (Figure 1c and d). In general,
ERK1/2 phosphorylation was found in only a small fraction of
nevus or melanoma cells, especially in the superficial
component of melanoma (Figure 1c–f) and AN (Figure 1h),
and more scattered in CN (Figure 1j). Activated ERK1/2 was
detected in seven of 24 CN (29%), 10 of 21 AN (48%), and 22
of 26 PM (85%) (Table 1).
To ensure that negative immunostaining was due to the
lack of phosphorylated ERK1/2, 11 negative cases (four CN,
four AN, and three melanomas) were stained with an
antibody targeting both phosphorylated and unphosphory-
lated ERK1/2. Diffuse cytoplasmic and nuclear staining was
seen with this antibody in the majority of normal and tumoral
cells in all cases (data not shown).
Association between BRAF mutation at codon 600 and MAPK
activation in nevi
BRAF mutations at codon 600 were found in 67% of CN,
62% of AN, and 58% of primary melanomas. BRAF
mutational status at codon 600 was correlated with MAPK
ERK1/2 activation by immunohistochemistry, finding that
23% of CN and 54% of AN with BRAF mutations have
activated MAPK (Table 1). In contrast, 93% of melanomas
with mutated BRAF have activated MAPK, this difference
being statistically significant (Table 1). In all groups, there
were tumors with activated MAPK, but without BRAF
mutation at codon 600 (Table 1).
B-Raf expression in melanocytic lesions
The antibody used to study B-Raf expression detects mutant
and wild-type protein (data not shown). B-Raf is expressed in
the epidermis, sebaceous glands, fibroblasts, and endothe-
lium in a diffuse and tenuous form, although in sweat glands
it is detected in a more intense form and there is no staining
in smooth muscle cells. The specificity of B-Raf antibody was
confirmed by incubating with B-Raf antibody and its blocking
peptide, resulting in the absence of immunostaining (Figure
1k and l). The expression of B-Raf is essentially cytoplasmic
(Figure 1m), and it is expressed in all the melanocytic tumors,
although the intensity of staining is variable. In general,
in melanoma, there is a more diffuse and intense immuno-
staining (Figure 1k, m, and n); in AN it is more intense
at the epidermis and junctional levels (Figure 1o); in CN,
the staining is notably weaker than in melanoma, and
it is preferentially seen at the epidermis or upper dermis
(Figure 1p).
DISCUSSION
Activation of MAPK was found in 29% of CN, 48% of AN,
and 85% of melanomas. Activated MAPK showed a similar
frequency as reported previously (Cohen et al., 2002).
Different reports show immunohistochemical expression of
activated MAPK in CN from 0 to 75% (Cohen et al., 2002;
Jorgensen et al., 2003; Saldanha et al., 2004). Cohen et al.
(2002), using the same antibody of the present study, found
MAPK activation in 22% of benign nevi with mild atypia, a
percentage similar to our results.
On the other hand, 23% of CN and 54% of AN with BRAF
mutation have activated MAPK. In contrast, 93% of
melanomas have activated MAPK in the presence of mutated
BRAF. AN lies in an intermediate position between CN and
melanoma, and this is related to its potential as a melanoma
precursor lesion. Nevi and melanomas with activated MAPK,
but without BRAF mutations at codon 600, were also found.
This situation can be explained by the following: (1) Ras
mutation: NRAS mutations of between 5 and 36% have been
detected in melanoma (Omholt et al., 2002) and in a small
fraction of CN (Pollock et al., 2003). (2) BRAF mutation at
codon 600 is the commonest mutation, but still about 10% of
BRAF mutations can be found at other codons (Wan et al.,
2004). (3) The presence of paracrine/autocrine growth factor
stimulation rather than RAS or BRAF mutations.
The absence of activation of MAPK in the presence of
BRAF mutation, especially in CN and AN, cannot be
explained by the absence of expression of B-Raf or total
ERK1/2, but by the existence of additional mechanisms
inducing activation of the pathway (ie, B-Raf overexpression
or complementary paracrine/autocrine growth factor stimula-
tion) (Satyamoorthy et al., 2003) and/or inhibitory mechan-
isms that reduce the expression or activity of B-Raf or other
protein(s) related to activation of ERK1/2:MAPK phosphatases
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Figure 1. Phosphorylated ERK1/2 and B-Raf expression in melanocytic lesions by immunohistochemistry. Activated MAPK (a–j) and B-Raf (k–p)
immunohistochemistry. (a) Formalin-fixed, paraffin-embedded SK-MEL-28 cells (BRAF V600E mutation) in culture media containing 10% of fetal bovine serum.
(b) Cells were cultured in starvation and with a MEK inhibitor (20 mM U0126). (c) Melanoma with intense activated MAPK staining. Lymphocytes (black dashed
oval) and endothelial cells (red dashed circle) were used as internal negative and positive controls. (d) The higher magnification picture shows nuclear and
cytoplasmatic staining. (e, f) Melanomas with positive staining. (g) AN negative for activated MAPK, but endothelium reacts with the antibody (red dashed oval).
(h) AN with positive staining for activated MAPK. CN negative (i) and positive (j) for activated ERK1/2. (k) PM with intense and diffuse B-Raf expression. (l) The
same melanoma as in (k), but incubated with B-Raf antibody and a 10-fold excess of B-Raf blocking peptide. (m) Melanoma showing intense cytoplasmic
staining. (n) Melanoma with intense expression of B-Raf. (o) AN with intense staining in the junctional component. (p) CN showing weak B-Raf expression,
greater in the upper dermis. Bar=100mm.
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(Brondello et al., 1997; Arbiser, 2003) and inhibitors of RAF
kinases (Schuierer et al., 2004). Although practically all
melanomas bearing mutated BRAF present activation of
MAPK and only a small fraction of the nevi follows the same
pattern, the existence of MAPK-independent cellular effects
of BRAF mutation in nevi cannot be discarded (Hindley and
Kolch, 2002; Ikenoue et al., 2003).
In summary, we have shown that in nevi, especially in CN,
BRAF mutation is not the only event to induce MAPK
activation, as it commonly occurs in melanoma. This fact
suggests the existence of still preserved control mechanisms
in most of the nevi and that these are lost in melanoma.
MATERIALS AND METHODS
Tissue samples
Formalin-fixed, paraffin-embedded tissues from 24 CN (19 intrader-
mal, four compound, and one junctional nevi), 21 AN, and 26
primary cutaneous melanomas (PM) (12 superficial spreading
melanomas, five nodular melanomas, three acral lentiginous
melanomas, two lentigo maligna melanomas, and four other
histological variants) from 64 patients were obtained from the files
of the Department of Pathology of the Catholic University School of
Medicine. The experiments conducted in this study were in
accordance with the Declaration of Helsinki Principles and had
institutional approval.
Antibodies and other reagents
The primary antibodies used in this study were rabbit polyclonal
phospho-p44/42 MAPK (Thr202/Tyr204) antibody to activated
ERK1/2 (New England BioLabs Inc., Beverly, MA), rabbit polyclonal
ERK1/2 antibody to total ERK1/2 (New England BioLabs Inc.), and
rabbit polyclonal Raf-B antibody (SC-166, Santa Cruz Biotechnol-
ogies Santa Cruz, CA). For B-Raf immunohistochemistry, a B-Raf
blocking peptide (SC-166P, Santa Cruz Biotechnologies Inc.) as a
control for antibody specificity was also used (1:50 dilution). The
specific Mek inhibitor U0126 (Favata et al., 1998) was purchased
from Promega (Madison, WI).
Immunohistochemistry
All specimens were fixed in 10% buffered neutral formalin,
dehydrated, and paraffin embedded. Immunostaining was performed
using 5-mm tissue sections placed on silanized glass slides. After
deparaffinization in xylene and graded alcohols, epitope retrieval
was performed. Target retrieval for activated ERK1/2 and total ERK1/
2 was made in 10 mM EDTA buffer (pH 8) in two steps of 16 and
6 minutes, respectively, in a microwave oven at 850 W. Epitope
retrieval for B-Raf was made in 10 mM EDTA buffer (pH 8) using
three rounds of 7 minutes each in a microwave oven at 850 W. After
epitope retrieval, endogenous peroxidase was blocked by immersing
the sections in 3% hydrogen peroxide for 15 minutes. Incubations
with primary antibodies were made at room temperature overnight
at the following dilutions: activated ERK1/2 1:100, total ERK1/2
1:200, and B-Raf 1:500. Dilutions were made using common
antibody diluent (Biogenex, San Ramon, CA). A streptavidin–biotin
multilink method (StrAviGen Multilink kit; Biogenex, San Ramon,
CA) using an automated staining System (Optimax I 6000, Biogenex)
was used for detection of reactivity. Sections were stained with a
secondary multilink antibody (1:70 dilution for 20 minutes), fol-
lowed by horseradish-peroxidase-labeled streptavidin complex (1:70
dilution for 20 minutes). 3-Amino-9-ethylcarbazole was used as
chromogen and applied for 10 minutes. Sections were counter-
stained with hematoxylin and mounted. All of the series included
positive and negative controls. Positive controls were sections of a
tissue specimen previously found to be positive for the antigen of
interest. The negative controls consisted of sections in which the
primary antibody had been excluded and replaced with common AB
diluent (Biogenex Inc.). Tumors with 41% of tumor cells staining for
activated ERK1/2 in the cytoplasm and/or nucleus were considered
Table 1. Relationship between BRAF mutation at codon 600 and expression of activated ERK1/2
(P-ERK1/2) in nevi and melanomas
P-ERK1/2 expression
Tumor
BRAF mutations
at codon 600 Yes No
Cases with mutated BRAF
and P-ERK1/2 expression
Common nevi (CN) 67% (16/24) 29% (7/24) 3/16 (23%)
Mutated BRAF 3 13
Wild-type BRAF 4 4
Atypical nevi (AN) 62% (13/21) 48% (10/21) 7/13 (54%)1
Mutated BRAF 7 6
Wild-type BRAF 3 5
Primary melanoma (PM) 58% (15/26) 85% (22/26)2,3 14/15 (93%)4,5
Mutated BRAF 14 1
Wild-type BRAF 8 3
1Represents Po0.064, between CN and AN.
2Represents Po0.001, between CN and PM.
3Represents P=0.010, between AN and PM.
4Represents Po0.001, between CN and PM.
5Represents P=0.002, between AN and PM.
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positive (Gioeli et al., 1999), and tumors with 45% of tumor cells
staining for B-Raf in the cytoplasm were considered positive. For
activated ERK1/2, endothelial cells and lymphocytes were used as
internal positive and negative controls, respectively (Gioeli et al.,
1999; Albanell et al., 2001). To ensure that negative immunostaining
was because of a lack of phosphorylated ERK1/2, 11 negative cases
were stained with a total ERK1/2 antibody. To evaluate the
immunohistochemical specificity of activated ERK1/2 antibody,
20 mM MEK inhibitor U0126 (Promega, Madison, WI) in SK-Mel28
cell line was used. After treatment, cells were formalin fixed and
paraffin embedded, before the immunostaining, and 3,3-diamino-
benzidine was used as chromogen.
Detection of BRAF mutations at codon 600
BRAF mutational data, for the most part, of microdissected samples
from archival paraffin-embedded tissues were available from a
previous study, and for new samples the same PCR-RFLP strategy
was used (Uribe et al., 2003). Briefly, a 170-bp product was obtained
using PCR amplification and later it was cut with TspRI. Mutated
DNA was cut into two fragments (135 and 35 bp) and wild-type
DNA was cut into three fragments (87, 48, and 35 bp). To test the
efficacy of the restriction enzyme in each digestion, DNA from one
case of a mutated melanoma sample was used as a positive control,
and DNA extracted from stromal cells was used as a negative control
for the mutation. At least two independent experiments were
performed on each sample to assure that the analysis was
reproducible.
Statistical analysis
A comparison between the expression of activated ERK1/2 and BRAF
mutation was performed using the Fisher exact test. All of the
statistical tests were conducted at the two-sided 0.05 level of
significance.
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